• Eliem Therapeutics Inc (NASDAQ: ELYM) has reported results from its Phase 2a trial investigating ETX-810 for lumbosacral radicular pain (LSRP).

• In the study, ETX-810 did not achieve statistically significant separation from placebo on the trial's primary endpoint, which assessed the change from baseline to week 4 in the weekly average of the daily pain score.

• Related: Eliem Announces Updated Development Plans For Its Delayed Depression Candidate.

• This result is consistent with the lack of separation from placebo observed in the Phase 2a clinical trial in diabetic peripheral neuropathic pain, as reported in April.

• Therefore, the company has elected to discontinue further development of ETX-810.

• The company recently updated that its capital is sufficient to fund key pipeline catalysts and operations until mid-2024.

• With the discontinuation of ETX-810, the company anticipates that its cash runway will extend beyond that time.

• Price Action: ELYM shares are down 33.90% at $2.01 during the premarket session on the last check Tuesday.

See more from Benzinga

• SEC Charges 11 People In $300M Crypto Ponzi Scheme

• BP's Q2 Earnings Triple On Rising Energy Prices, Boosts Quarterly Dividend

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.